Research programme: Indications Discovery - Melior Discovery
Latest Information Update: 29 Aug 2011
At a glance
- Originator Melior Discovery
- Developer Merck & Co
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 29 Aug 2011 Preclinical development is ongoing in USA
- 10 Nov 2006 Melior Discovery and Merck & Co. have entered into a research collaboration
- 27 Jul 2005 Preclinical trials in Undefined in USA (unspecified route)